This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | MicrobiomeTrials
← Back to trials NCT05614739
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2023-01-12Est. Completion: 2027-06
Enrollment target: 535 participantsLocations University of Arizona - Cancer Center, Tucson, Arizona, United States City of Hope, Duarte, California, United States University of California, Los Angeles (UCLA) - Division of Hematology-Oncology, Los Angeles, California, United States University of California - Irvine, Orange, California, United States University of California (UC) Davis Comprehensive Cancer Center, Sacramento, California, United States Stanford Medicine Cancer Center, Stanford, California, United States Advent Health, Orlando, Florida, United States Emory University Hospital, Atlanta, Georgia, United States The University of Chicago Medical Center (UCMC), Chicago, Illinois, United States Indiana University (IU) Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States Ochsner Clinic Foundation, New Orleans, Louisiana, United States Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States Other microbiome trials you might be interested in Breast Cancer Small Cell Lung Cancer Ovarian Cancer Gastric Cancer Hormone-receptor-positive Breast Cancer Hormone Receptor Positive HER-2 Negative Breast Cancer Advanced Solid Tumor Endometrial Cancer Prostate Cancer TNBC - Triple-Negative Breast Cancer GastroEsophageal Cancer Bladder Cancer
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to a…
Newport Beach, United States Est. completion Aug 31, 2026
Washington University in St. Louis, St Louis, Missouri, United States
New York University (NYU), New York, New York, United States
Weill Cornell Medicine, New York, New York, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Columbia University, New York, New York, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Rochester - Wilmot Cancer Institute, Rochester, New York, United States
Montefiore Medical Center, The Bronx, New York, United States
University of North Carolina (UNC) - Chapel Hill, Chapel Hill, North Carolina, United States
University of Cincinnati Medical Center (UCMC), Cincinnati, Ohio, United States
The Ohio State University (OSU), Columbus, Ohio, United States
University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma, United States
Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Sarah Cannon and HCA Research Institute, Nashville, Tennessee, United States
Tennessee Oncology, Nashville, Tennessee, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
University of Texas Southwestern, Dallas, Texas, United States
Texas Oncology, P.A, Dallas, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
University of Utah, Salt Lake City, Utah, United States
University of Vermont Medical Center, Burlington, Vermont, United States
St Vincent's Hospital, Darlinghurst, Australia
Calvary Mater Newcastle, Hunter Region, NSW, Australia
GenesisCare North Shore, St Leonards, Australia
Macquarie University, Sydney, Australia
Princess Margaret Hospital, Toronto, Canada
British Columbia Cancer Agency, Vancouver, Canada
Beijing Cancer hospital, Beijing, China
Beijing Hospital, Beijing, China
Sun Yat-Sen University- Cancer Center, Guangdong, China
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Zhejiang Provincial People's Hospital, Zhejiang, China
Institut Bergonie, Bordeaux, France
Centre Leon Berard, Lyon, France
Institut Gustave Roussy, Villejuif, France
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), München, Germany
Universitaetsklinikum Tuebingen, Tübingen, Germany
Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel
Sheba Medical Center, Tel Litwinsky, Israel
IRCCS Ospedale San Raffaele, Milan, Italy
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, Italy
National Cancer Center Hospital East, Chiba, Japan
Aichi Cancer Center Hospital, Nagoya, Japan
National Cancer Center Hospital, Tokyo, Japan
Cancer Institute Hospital of JFCR, Tokyo, Japan
Erasmus MC, GE Rotterdam, Netherlands
Haukeland University Hospital, Bergen, Norway
Oslo University Hospital, Oslo, Norway
Seoul National University Hospital, Seoul, South Korea
Severance Hospital, Yonsei University Health System, Seoul, South Korea
Asan Medical Center, Seoul, South Korea
Samsung Medical Center, Seoul, South Korea
Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Spain
Fundacion MD Anderson International Espana, Madrid, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC, Madrid, Spain
Hospital Universitario Marques De Valdecilla, Santander, Spain
The Christie NHS Foundation Trust, Manchester, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom Gastrointestinal Neoplasms Pancreatic Neoplasms Liver Neoplasm Oesophageal Cancer Gastrointestinal Cancer Pancreatic Cancer Liver Cancer Prehabilitation Cancer Rehabilitation
Major visceral oncologic surgery is associated with high postoperative morbidity, prolonged hospitalization, delayed rec…
Saint Veit Im Pongau, Austria Est. completion Jun 2027
Adenocarcinoma Prostate Cancer Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type
Background:
Prostate cancer is the second most common cause of cancer-related death among men in the United States. Ear…
Bethesda, United States Est. completion Jun 15, 2027